Loading...
Market
Will additional case studies showing HIV remission using wildtype CCR5 stem cells be published by March 31, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Peer-reviewed medical journals and publications
Story
NatureMedicine: Patient Achieves HIV Remission with Wildtype CCR5 Stem Cells
Sep 5, 2024, 06:30 PM
A male patient has achieved durable HIV remission after receiving an allogenic hematopoietic stem cell transplant from a donor with wildtype CCR5 cells, according to a case study by NatureMedicine. This marks the first remission with wildtype CCR5 cells. The case study highlights the potential of using stem cells from individuals who naturally lack CCR5 receptors to cure HIV. This development follows controversial research by He Jiankui, a Chinese professor who used CRISPR to edit the genomes of two babies to provide them with natural resistance to HIV, which raised significant ethical concerns.
View original story
Similar markets
Yes • 50%
No • 50%
Yes, in the USA • 25%
Yes, in Europe • 25%
Yes, in Asia • 25%
No • 25%
1-2 more people • 25%
3-4 more people • 25%
5 or more people • 25%
No increase • 25%
7 • 25%
8 • 25%
9 • 25%
10 or more • 25%
Yes • 50%
No • 50%
Significant reduction in HIV levels (over 1000-fold) • 25%
Moderate reduction in HIV levels (100-1000 fold) • 25%
Minimal reduction in HIV levels (less than 100 fold) • 25%
No significant reduction in HIV levels • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%